Validation of prognostic models of lung cancer
Principal Investigator
Name
Thomas Callender
Degrees
M.B.Ch.B., M.Sc.
Institution
University College London
Position Title
Wellcome Trust Clinical PhD Training Fellow
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-801
Initial CDAS Request Approval
Jun 21, 2021
Title
Validation of prognostic models of lung cancer
Summary
Lung cancer remains the foremost cause of death from cancer worldwide. Screening for lung cancer could lead to a ~20% reduction in lung-cancer–specific mortality. However, current eligibility criteria – age and cumulative smoking exposure – remain contested, and several studies have shown the potential benefits of risk-based eligibility for screening. The purpose of this project is to validate prognostic models of lung cancer that have been developed in the UK Biobank in order to determine eligibility for lung cancer screening.
Aims
1. To validate the predictive performance (calibration & discrimination) of prognostic models of lung cancer developed in the UK Biobank prior to implementation.
Collaborators
Professor Sam Janes, University College London
Related Publications
-
Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
Callender T, Imrie F, Cebere B, Pashayan N, Navani N, van der Schaar M, Janes SM
PLoS Med. 2023 Oct; Volume 20 (Issue 10): Pages e1004287 PUBMED